Cutaneous relapse of primary breast diffuse large B-cell lymphoma

This is the authors' abstract. We don't add key points for this paper.

Diffuse large B-cell lymphoma (DLBCL) is an aggressive neoplasm of large B lymphoid cells characterized by a histologically diffuse growth pattern.1 It is the most prevalent form of non-Hodgkin lymphoma globally, often seen in older individuals, and is typically identified by the presence of rapidly proliferating tumors in 1 or more lymph nodes and extranodal sites upon initial presentation.1 Although the landscape of DLBCL treatment is quickly evolving, the current standard of care remains rituximab plus cyclophosphamide, vincristine, doxorubicin, and prednisone.